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vessel vasculitis are not associated with
disease activity but are influenced by age
and statins
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Introduction: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large vessel vasculitides (LVV) that usually
present as granulomatous inflammation in arterial walls. High mobility group box 1 (HMGB1) is a nuclear protein
that acts as an alarmin when released by dying or activated cells. This study aims to evaluate whether serum
HMGB1 can be used as a biomarker in LVV.
Methods: Twenty-nine consecutive TA patients with 29 healthy controls (HC) were evaluated in a cross-sectional
study. Eighteen consecutive GCA patients with 16 HC were evaluated at the onset of disease and some of them
during follow-up. Serum HMGB1 levels were measured by enzyme-linked immunosorbent assay.
Results: In GCA patients at disease onset mean serum HMGB1 levels did not differ from HC (5.74 ± 4.19 ng/ml vs.
4.17 ± 3.14 ng/ml; p = 0.230). No differences in HMGB1 levels were found between GCA patients with and without
polymyalgia rheumatica (p = 0.167), ischemic manifestations (p = 0.873), systemic manifestations (p = 0.474) or
relapsing disease (p = 0.608). During follow-up, no significant fluctuations on serum HMGB1 levels were observed
from baseline to 3 months (n = 13) (p = 0.075), 12 months (n = 6) (p = 0.093) and at the first relapse (n = 4)
(p = 0.202). Serum HMGB1 levels did not differ between TA patients and HC [1.19 (0.45–2.10) ng/ml vs. 1.46
(0.89–3.34) ng/ml; p = 0.181] and no difference was found between TA patients with active disease and in remission
[1.31 (0.63–2.16) ng/ml vs. 0.75 (0.39–2.05) ng/ml; p = 0.281]. HMGB1 levels were significantly lower in 16 TA patients
on statins compared with 13 patients without statins [0.59 (0.29–1.46) ng/ml vs. 1.93 (0.88–3.34) ng/ml; p = 0.019].
Age was independently associated with higher HMGB1 levels regardless of LVV or control status.
Conclusions: Patients with TA and GCA present similar serum HMGB1 levels compared with HC. Serum HMGB1 is
not useful to discriminate between active disease and remission. In TA, use of statins was associated with lower
HMGB1 levels. HMGB1 is not a biomarker for LVV.* Correspondence: alexandre_wagner@uol.com.br
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Takayasu arteritis (TA) and giant cell arteritis (GCA) are
large vessel vasculitides (LVV) characterized by granu-
lomatous inflammation of the vessel wall [1]. Although
both diseases present significant overlap in features and
some similarities in the distribution of angiographic le-
sions [2], TA predominantly affects young females and
involves the aorta and its main branches whereas GCA
affects predominantly branches of carotid and vertebral
arteries in individuals older than 50 years [1].
Despite clinical symptoms, acute phase reactants and
vascular imaging help to assess disease activity in LVV,
there is a need for novel biomarkers for diagnosis, progno-
sis and to distinguish active disease from damage or infec-
tion. In TA, active disease is associated with higher serum
levels of pentraxin-3, matrix metalloproteinase 9 (MMP-9),
interleukin (IL)-6, IL-8, IL-18, B cell-activating factor
(BAFF), monocyte chemoattractant protein-1 (MCP-1)
and regulated on activation, normal T cell expressed and
secreted (RANTES) [3–9]. In GCA, high serum levels of
tumor necrosis factor alpha (TNF-α), IL-6, IL-10, che-
mokine (C-X-C motif) ligand 9 (CXCL9) and BAFF are
associated with active disease while serum levels of CC
chemokines CCL2 and CCL11 are decreased at disease on-
set [10–14]. Moreover, adaptive immunity is triggered dur-
ing GCA pathogenesis manifested by T helper (Th)1 andTable 1 Demographic, disease features and therapy of patients with
Variables GCA HC p Va
(n = 18) (n = 16)
Demographic features
Age, years 72.0 (63.7–75.0) 68.5 (63.0–72.0) 0.643 A
Females, n (%) 14 (77.8) 11 (68.8) 0.551 Fe
Disease features and therapy
GCA Results TA
Headache, n (%) 12 (66.7) D




Jaw claudication, n (%) 6 (33.3) A
Visual symptoms, n (%) 4 (22.2) Re
Polymyalgia rheumatica, n (%) 4 (22.2) St
Headache, n (%) 12 (66.7) Pr
ESR, mm/1st hour 69.6 ± 28.7 Pr
CRP, mg/l 40.0 (20.2–84.2) Im
Positive TAB, n/total 8/11 Bi
Positive PET-CT scan, n/total 13/15
Continuous variables are presented as mean ± standard deviation or as median and
CRP C-reactive protein, ESR erythrocyte sedimentation rate, GCA giant cell arteritis, H
tomography, TA Takayasu arteritis, TAB temporal artery biopsyTh17 responses with the production of interferon (IFN)-γ
and IL-17A, which enhance arterial inflammation [15, 16].
High mobility group box 1 (HMGB1) is a nuclear non-
histone protein that acts as an alarmin when released
into the extracellular milieu either by cellular death or
upon activation of inflammatory cells, e.g. macrophages
by lipopolysaccharide (LPS) or IFN-γ [17, 18]. High
serum HMGB1 levels have been observed in infectious
diseases, atherosclerosis, mechanical trauma, cancer, and
in systemic autoimmune diseases such as systemic lupus
erythematosus (SLE) [19–23]. In systemic vasculitis, high
serum HMGB1 levels were observed in Kawasaki dis-
ease, immunoglobulin (Ig)A vasculitis, and in patients
with antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitis, especially in granulomatosis with
polyangiitis (GPA) with granulomatous manifestations
[24–27]. Serum HMGB1 levels have not been evalu-
ated in patients with LVV. This study aims to evaluate
serum HMGB1 levels as a surrogate marker of disease
activity in patients with LVV and associations between
serum HMGB1 and acute phase reactants, disease
manifestations and therapy in patients with TA and
GCA. Due to epidemiological differences in the preva-
lence of both diseases, patients with TA were recruited
from Brazil whereas GCA patients were recruited
from The Netherlands.giant cell arteritis at disease onset and Takayasu arteritis
riables TA HC p
(n = 29) (n = 29)
ge, years 38.0 (34.5–48.5) 38.0 (27.5–48.5) 0.392
males, n (%) 28 (96.6) 27 (93.1) 0.553
Results
isease duration, months 108 (60–186)
ngiographic type V, n (%) 16 (55.2)
evious ischemic events, n (%) 11 (37.9)
ctive disease, n (%) 11 (37.9)
mission, n (%) 18 (62.1)
atins, n (%) 16 (55.2)
ednisone, n (%) 16 (55.2)
ednisone daily dose, mg 8.7 (5.0–28.7)
munosuppressive agents, n (%) 19 (65.5)
ological agents, n (%) 9 (31.0)
interquartile range
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Study population
The study comprised 18 GCA patients with 16 healthy
controls (HC), both from the University Medical Center
Groningen (UMCG), The Netherlands (Table 1), and 29
consecutive TA patients from Universidade Federal de São
Paulo (UNIFESP), Brazil with 29 HC from the same region
(Table 1). Inclusion criterion for TA patients was the ful-
fillment of the 1990 American College of Rheumatology
(ACR) classification criteria [28] while the exclusion cri-
teria were current chronic infectious disease, malignancy,
and pregnancy. GCA patients were included if they
fulfilled the 1990 ACR criteria [29] or when presenting
compatible manifestations associated with an enhanced
18F-fluorodeoxyglucose uptake in large vessels by positron
emission computed tomography (18FDG-PET/CT). Exclu-
sion criteria for GCA included current chronic infectious
disease and malignancy. The study was approved by the
Ethics Committee on Research from UNIFESP and by the
Medical Ethical Committee of UMCG and complied with
the Declaration of Helsinki. All necessary consent was
provided from all participants involved in this study.
Active disease in GCA was considered if patients pre-
sented manifestations of active disease (e.g. temporal
headache, optic neuritis, jaw claudication) not attributable
to other causes and/or polymyalgia rheumatica (PMR)
symptoms with an increase in ESR > 30 mm/hour whereas
remission was considered in the absence of GCA mani-
festations with normal ESR [30]. Kerr’s criteria and the
Indian Takayasu activity score 2010 (ITAS2010) with
acute phase response (ITAS.A) using ESR or CRP were
employed to ascertain disease activity in TA [31, 32].
In the 18 GCA patients, blood samples were collected at
disease onset prior to glucocorticoid therapy and follow-up
samples were obtained from 13 patients at 3 months and
from six patients at 12 months. Blood samples were col-
lected from 29 TA patients as a cross-sectional evaluation.
Serum HMGB1
Serum HMGB1 levels were determined by enzyme-linked
immunosorbent assay (ELISA) using a commercial kit
(Shino Test Corp., Sagamihara, Kanagawa, Japan) according
to the manufacturer’s instructions. Results were expressed
in nanograms per milliliter.
Statistical analysis
Statistical analysis was performed using IBM SPSS soft-
ware for Windows version 20.0 (IBM Corp, Armonk, NY,
USA) and graphs were created with GraphPad Prism ver-
sion 3.02 (GraphPad Software, La Jolla, CA, USA). Mean ±
standard deviation or median and interquartile range were
used to present normally distributed and nonnormally
distributed continuous variables, respectively. Categorical
variables were presented as total number and percentage.Comparisons between groups were performed using Stu-
dent’s t test or Mann–Whitney U test for continuous data
or using chi-square test or Fisher’s exact test for categorical
variables. Correlations between numerical data were per-
formed with Spearman’s correlation coefficient. A linear
regression model was built to analyze whether age and
the diagnosis of LVV were independently associated with
serum HMGB1 levels. Receiver operating characteristic
(ROC) analysis was performed to find out the HMGB1
cutoff with the best sensitivity and specificity to differenti-
ate GCA from TA. The cutoff value was chosen from the
maximized sum of sensitivity and specificity. Paired t test
or Wilcoxon’s test were used to analyze longitudinal data.
The significance level accepted was 5 % (p < 0.05).Results
Disease features and therapy of GCA and TA patients
Disease features and therapy of GCA and TA patients
are described in Table 1. After the first evaluation, all
GCA patients were treated with high-dose prednisolone
(60 mg/day) with slow tapering after improvement of
disease symptoms and laboratory abnormalities. Disease
relapse was observed in four (22.2 %) GCA patients and
the median time to the first relapse after diagnosis was
6.0 months (6.0–15.0). Methotrexate 10–15 mg per week
was added to two patients (11.1 %) after the first relapse
during steroid tapering. Five GCA patients (27.8 %) were
on statins at disease onset.
Previous ischemic events in TA included unstable an-
gina (four patients), stroke (three patients), acute myo-
cardial infarction (two patients), transient ischemic
attacks and mesenteric ischemia in one patient each.
Two TA patients were treated only with prednisone
whereas the remainder used either an immunosuppres-
sive drug or a biologic agent. ESR, ITAS.A ESR and
ITAS.A C-reactive protein (CRP) values were signifi-
cantly higher in TA patients with active disease than in
those in remission, whereas there was a trend for higher
serum CRP levels in patients with active disease. No sig-
nificant differences could be found between patients
with active disease and remission regarding therapy
(Table 2).HMGB1 levels in giant cell arteritis
In GCA patients with active disease at onset and prior to
therapy mean serum HMGB1 levels did not differ between
patients and HC (5.74 ± 4.19 ng/ml vs. 4.17 ± 3.14 ng/ml;
p = 0.230) (Fig. 1). Furthermore, among GCA patients
mean serum HMGB1 levels at onset were not higher in
patients with or without PMR [1.25 (0.21–10.50) ng/ml vs.
5.42 (2.94–8.92) ng/ml; p = 0.167], cranial ischemic mani-
festations (5.56 ± 3.31 ng/ml vs. 5.89 ± 4.95 ng/ml; p =































t2:1 Table 2 Comparison between patients with Takayasu arteritis with active disease and in remission
t2:2 Variables Active disease (n = 11) Remission (n = 18) p
t2:3 HMGB1, ng/ml 1.31 (0.63–2.16) 0.75 (0.39–2.05) 0.281
t2:4 ESR, mm/1st hour 39.0 (25.0–68.0) 17.5 (8.0–25.5) 0.017
t2:5 CRP, mg/l 6.0 (4.4–24.9) 2.0 (0.1–10.7) 0.053
t2:6 ITAS2010 3.0 (2.2–5.2) – –
t2:7 ITAS.A ESR 3.5 (2.0–6.2) 1.0 (1.0–1.7) 0.001
t2:8 ITAS.A CRP 5.1 ± 2.5 2.1 ± 0.9 0.012
t2:9 Statins, n (%) 7 (63.6) 9 (50.0) 0.702
t2:10 Prednisone, n (%) 6 (54.5) 10 (55.6) 0.958
t2:11 Prednisone daily dose, mg 20.0 (7.5–45.0) 5.0 (2.5–13.7) 0.055
t2:12 Immunosuppressive agents, n (%) 7 (63.6) 12 (66.7) 0.868
t2:13 Biological agents, n (%) 3 (27.3) 6 (33.3) 0.732
t2:14 Continuous variables are presented as median and interquartile range or as mean ± standard deviation
t2:15 CRP C-reactive protein, ESR erythrocyte sedimentation rate, ITAS Indian Takayasu activity score, ITAS.A Indian Takayasu activity score with acute phase response,
t2:16 HMGB1 high mobility group box 1, n number of patients
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3.31 ng/ml vs. 6.02 ± 4.47 ng/ml; p = 0.608), respectively.
Mean serum HMGB1 levels in GCA patients were
5.74 ± 4.19 ng/ml at baseline, 5.18 ± 3.98 ng/ml at 3
months, 8.19 ± 6.80 ng/ml at 12 months, and 6.23 ± 2.48
ng/ml at the first relapse. During follow-up, no signifi-
cant fluctuations on serum HMGB1 levels were ob-
served from baseline levels to 3 and 12 months (Fig. 2).
Moreover, serum HMGB1 levels in relapsing patients
were not different from their levels at disease onset (p =
0.825), at 3 months (p = 0.629), at 12 months (p = 0.601)
and from HC (p = 0.170) (Table 3). In GCA patients
no correlation was present between HMGB1 and ESR
(rho = −0.220; p = 0.380) or between HMGB1 and CRP
levels (rho = −0.258; p = 0.301).218
Fig. 1 Serum high mobility group box 1 (HMGB1) levels in patients
with giant cell arteritis (GCA) and healthy controls (HC). GCA patients
at disease onset present similar serum HMGB1 levels compared
to HCSerum HMGB1 in Takayasu arteritis
As depicted in Fig. 3, serum HMGB1 levels did not differ
between TA patients with active disease [1.31 (0.63–2.16)
ng/ml], patients in remission [0.75 (0.39–2.05) ng/ml] and
HC [1.46 (0.89–3.34) ng/ml] (p = 0.220). Similar median
serum HMGB1 levels were found in TA patients with and
without previous ischemic events [1.53 (0.42–3.34) ng/ml
vs. 0.97 (0.50–1.93) ng/ml; p = 0.486]. There was no dif-
ference in serum HMGB1 levels in TA patients under
prednisone therapy compared with those not receiving
prednisone [1.13 (0.45–2.34) ng/ml vs. 1.31 (0.36–1.94)
ng/ml; p = 0.676] or between TA patients receiving im-
munosuppressive agents compared with those on bio-
logical agents [1.59 (0.43–2.45) ng/ml vs. 0.59 (0.42–0.96);
p = 0.140]. However, serum HMGB1 levels were signifi-
cantly lower in TA patients on statins compared withFig. 2 Longitudinal levels of serum high mobility group box 1
(HMGB1) in patients with giant cell arteritis (GCA). Serum HMGB1 in



















































t3:1 Table 3 Longitudinal data on disease activity and serum HMGB1 levels in patients with giant cell arteritis
t3:2 Variables Baseline (n = 18) 3 months (n = 13) 12 months (n = 6) Relapse (n = 4)
t3:3 HMGB1, ng/ml 5.74 ± 4.19 5.18 ± 3.98 8.19 ± 6.80 6.23 ± 2.48
t3:4 ESR, mm/1st hour 69.6 ± 28.7 15.1 ± 6.6 21.0 ± 4.9 57.5 ± 24.2
t3:5 CRP, mg/l 40.0 (20.2–84.2) 2.5 (2.5–7.0) 8.0 (5.1–14.7) 38.5 (12.0–82.2)
t3:6 Prednisolone, mg/day – 20.0 (18.7–27.5) 18.7 (3.7–30.0) 6.2 (1.2–9.3)
t3:7 Continuous variables are presented as median and interquartile range or as mean ± standard deviation
t3:8 CRP C-reactive protein, ESR erythrocyte sedimentation rate, HMGB1 high mobility group box 1
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vs. 1.93 (0.88–3.34) ng/ml; p = 0.019] (Fig. 4).
No correlation could be observed between serum
HMGB1 levels and ESR (rho = 0.104; p = 0.590), CRP
(rho = 0.090; p = 0.642), ITAS2010 (rho = 0.230; p = 0.231),
ITAS.A ESR (rho = 0.216; p = 0.261) or ITAS.A CRP
(rho = 0.070; p = 0.720).
Comparison between Takayasu arteritis and giant cell
arteritis regarding serum HMGB1 levels
GCA patients at disease onset presented significantly
higher median serum HMGB1 levels compared with TA
patients with active disease [4.70 (2.55–8.92) ng/ml vs.
1.31 (0.63–2.16) ng/ml; p = 0.0075] (Fig. 5). Even when
GCA and TA patients without statins were analyzed sep-
arately, serum HMGB1 levels were significantly higher
in GCA patients compared to TA patients [5.06 (2.86–
10.0) ng/ml vs. 1.80 (0.63–3.34); p = 0.015].
Higher serum HMGB1 levels observed in GCA com-
pared with TA seems to be an effect of aging, since
serum HMGB1 levels were also higher in GCA controls
than in TA controls [2.98 (1.70–6.23) ng/ml vs. 1.46
(0.89–3.34) ng/ml; p = 0.019]. A weak correlation was
found between serum HMGB1 levels and age in all study
participants (rho = 0.244; p = 0.019) while in a linear re-
gression model, age was independently associated withFig. 3 Serum high mobility group box 1 (HMGB1) levels in patients
with Takayasu arteritis (TA) and healthy controls (HC). TA patients
with active disease and in remission present similar serum HMGB1
levels compared with HCserum HMGB1 levels (β = 0.056; p = 0.003; R2 = 0.099),
regardless of the diagnosis of LVV or control status.
ROC analysis of GCA and TA patients showed that the
best HMGB1 cutoff value for differentiating GCA from
TA is 2.17 ng/ml with 83.3 % sensitivity and 79.3 %
specificity.Discussion
In this study, we observed that patients with active LVV
present similar serum HMGB1 levels compared with pa-
tients in remission and HC. TA patients in remission
and those with relapsing disease were already under
therapy and the use of statins was associated with lower
serum HMGB1 levels. Furthermore, in GCA patients
with active disease prior to therapy, serum HMGB1
levels were not different from HC but were higher than
HMGB1 levels found in TA patients with active disease.
The need for reliable biomarkers for disease activity is
an issue of utmost importance in TA. The evaluation of
disease activity is a challenge; since the disease course is
protracted and silent relapses are common, occurring in
up to 96 % of patients who attained remission. It is not
easy to define when the disease is actually in remission
and most patients develop new angiographic lesions over
time usually without clear manifestations of diseaseFig. 4 Influence of statins use on serum high mobility group box 1
(HMGB1) levels in patients with Takayasu arteritis (TA). Statins use


























































































Fig. 5 Serum high mobility group box 1 (HMGB1) levels in patients
with giant cell arteritis (GCA) and Takayasu arteritis (TA) with active
disease. GCA patients at disease onset and prior to any therapy
present higher serum HMGB1 levels than TA patients with active
disease but already on treatment with prednisone and
immunosuppressive or biological agents
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help medical decisions for TA.
Granulomatous inflammation and vessel wall necrosis
are well-known features of LVV [34]. Either necrosis or in-
filtrating macrophages are important sources of HMGB1
release into the extracellular milieu that in turn activate
innate and adaptive immunity [35]. Patients with GPA and
predominant granulomatous inflammation present higher
serum HMGB1 levels compared with GPA patients with
predominantly vasculitic manifestations [25]. Thus, we
evaluated associations between disease activity in LVV and
serum HMGB1 levels. Unfortunately, no difference could
be found between patients with active disease and remis-
sion or between patients with LVV and HC.
On the other hand, GCA patients at disease onset and
prior to therapy presented serum HMGB1 levels that
were similar to those of HC, and no association could be
found between HMGB1 and acute phase reactants, dis-
ease manifestations or disease relapse. Moreover, during
follow-up no significant fluctuations in serum HMGB1
levels were observed in GCA patients. Novel biomarkers
in GCA would help to recognize active disease in pa-
tients with signs and symptoms of GCA but normal
acute phase reactants. However, serum HMGB1 levels
were not increased in patients with active disease.
Serum HMGB1 levels were significantly higher in
GCA patients than in TA patients, and even though the
ROC analysis showed that a cutoff value of 2.17 ng/ml
in HMGB1 levels would help to differentiate GCA from
TA, we believe that it is unlikely that in clinical practice
it would replace the 50-year-old cutoff point used to dif-
ferentiate both entities [1]. Furthermore, GCA controls
had higher serum HMGB1 than TA controls. These
findings indicate that serum HMGB1 levels increase dur-
ing aging and may be influenced by the burden ofatherosclerosis in older individuals. In mice, the age-
dependent DNA double-strand break is associated with
a reduction of nuclear HMGB1 in neurons leading to an
increased release of extracellular HMGB1 [36]. However,
in a population study performed in Japan with 626 sub-
jects, aging did not seem to affect serum HMGB1 levels
in healthy subjects [37]. In the present study, although
only a weak correlation was found between age and
serum HMGB1 levels, age was independently associated
with serum HMGB1 levels regardless of the diagnosis of
LVV or control status.
We found a strong association between statins and
lower serum HMGB1 levels in 16 patients with TA (55.2
%). Recently, lower HMGB1 levels were observed in
hyperlipidemic patients and in GPA patients in remis-
sion both on statin therapy [38, 39]. Moreover, atorva-
statin was able to reduce in vitro the release of HMGB1
in stimulated human umbilical vein endothelial cell
(HUVEC) cultures. This indicates that the inhibition of
HMGB1 release by activated cells is one of the pleio-
tropic effects of statins [39]. Other drugs may also influ-
ence HMGB1 release from cells such as dexamethasone
and metformin [40, 41]. These findings may explain in
part why TA patients already under treatment presented
serum HMGB1 levels similar to HC.
The role of statins in GCA has still to be determined.
No impact on relapse rate or on the prevention of severe
ischemic events was observed in retrospective studies.
However, conflicting results were found regarding the
influence of statins on acute phase reactants and daily
glucocorticoid dose in GCA patients using statins [42–44].
In TA patients, a retrospective study could not find any
difference in ischemic events between patients with and
without statins but associations with disease activity were
not analyzed [45]. In the present study, more TA patients
used statins than GCA patients at diagnosis although this
difference was not statistically significant (data not shown).
This could be due to the long disease course of our TA pa-
tients in comparison with the GCA patients who were eval-
uated at disease onset.
Limitations of this study are its mainly cross-sectional
nature and the inclusion of patients already on therapy
for TA, whereas the low number of patients and the
short-term follow-up period are limitations for the GCA
patients. Nevertheless, the data seem robust enough to
conclude that HMGB1 is not a suitable biomarker in
LVV in contrast to SLE [23].
Conclusions
Serum HMGB1 levels were neither different between pa-
tients with LVV and HC, nor between patients with ac-
tive disease and those in remission. Therefore, serum
HMGB1 is not a useful biomarker for LVV. Moreover,
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apy with statins seems to lead to lower serum HMGB1
levels.
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